Cargando…

Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases

Bruton’s tyrosine kinase (BTK) plays a crucial role in B-cell receptor and Fc receptor signaling pathways. BTK is also involved in the regulation of Toll-like receptors and chemokine receptors. Given the central role of BTK in immunity, BTK inhibition represents a promising therapeutic approach for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Datong, Gong, He, Meng, Fancui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399599/ https://www.ncbi.nlm.nih.gov/pubmed/34443496 http://dx.doi.org/10.3390/molecules26164907

Ejemplares similares

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
por: Alu, Aqu, et al.
Publicado: (2022)

Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors
por: Bose, Prithviraj, et al.
Publicado: (2021)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
por: Wang, Haoran, et al.
Publicado: (2021)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2021)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

The Development of BTK Inhibitors: A Five-Year Update
por: Tasso, Bruno, et al.
Publicado: (2021)

Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease
por: Rip, Jasper, et al.
Publicado: (2019)

Recent Advances in Autoimmune Thyroid Diseases
por: Yoo, Won Sang, et al.
Publicado: (2016)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
por: Brullo, Chiara, et al.
Publicado: (2021)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives
por: Ciesielski, Oskar, et al.
Publicado: (2022)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
por: Carnero Contentti, Edgar, et al.
Publicado: (2022)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
por: Rogers, Andrew, et al.
Publicado: (2020)

Kinase inhibitors for the treatment of inflammatory and autoimmune disorders
por: Bhagwat, Shripad S.
Publicado: (2008)

Recent Advances in Autoimmune Diseases
por: Jones, David E J
Publicado: (2000)

Low-dose Btk inhibitors: an ‘aspirin’ of tomorrow?
por: Payrastre, Bernard, et al.
Publicado: (2021)

Classical and recent advances in the treatment of inflammatory bowel diseases
por: Sales-Campos, H., et al.
Publicado: (2014)

Impaired B Cell Apoptosis Results in Autoimmunity That Is Alleviated by Ablation of Btk
por: Wright, Jacqueline A., et al.
Publicado: (2021)

Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives
por: Ghiboub, Mohammed, et al.
Publicado: (2021)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022)

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
por: Lewis, Katharine L, et al.
Publicado: (2021)

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
por: Arthur, Rachael, et al.
Publicado: (2020)

Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
por: Muñoz, Javier, et al.
Publicado: (2022)

Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases
por: Park, Youngjae, et al.
Publicado: (2022)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
por: Nasillo, Vincenzo, et al.
Publicado: (2022)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
por: O’Brien, Susan M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t1qkfo4971kqqq3qf2hj98mqp2